

Table 1. Revised and new CLSI breakpoints†

Drug (dosage)‡	MIC						Disk					
	New			Old			New			Old		
	S	I	R	S	I	R	S	I	R	S	I	R
Aztreonam (1g q8)	≤4	8	≥16	≤8	16	≥32	≥21	18-20	≤17	≥22	16-21	≤15
Cefazolin (2g q8)	≤2	4	≥8	≤8	16	≥32	≥23	20-22	≤19	≥18	15-17	≤14
Cefotaxime (1g q8)	≤1	2	≥4	≤8	16-32	≥64	≥26	23-25	≤22	≥23	15-22	≤14
Ceftazidime (1g q8)	≤4	8	≥16	≤8	16	≥32	≥21	18-20	≤17	≥18	15-17	≤14
Ceftizoxime (1g q12)	≤1	2	≥4	≤8	16-32	≥64	≥25	22-24	≤21	≥20	15-19	≤14
Ceftriaxone (1g q24)	≤1	2	≥4	≤8	16-32	≥64	≥23	20-22	≤19	≥21	14-20	≤13
Doripenem (500mg q8)	≤1	2	≥4	NA*			≥23	20-22	≤19	≥23	20-22	≤15
Ertapenem (1g q24)	≤0.25	0.5	≥1	≤2	4	≥8	≥23	20-22	≤19	≥19	16-18	≤15
Imipenem (1g q8)	≤1	2	≥4	≤4	8	≥16	≥23	20-22	≤19	≥16	14-15	≤13
Meropenem (1g q8)	≤1	2	≥4	≤4	8	≥16	≥23	20-22	≤19	≥16	14-15	≤13

† S, susceptible; I, intermediate; R, resistant

‡ Dosage used to establish breakpoints

*NA, not applicable

Reference

Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.